摘要
目的：评价干扰素α（IFN-α）对肝炎病毒相关性血小板减少症患者的疗效。方法：对20例肝炎病毒相关性血小板减少症患者进行IFN-α治疗，IFN-α具体用法：3MU，皮下注射，1周2次，至少2个月。结果：20例患者中男性14例，女性6例，中位年龄36．5（7～50）岁。HBV阳性15例，HCV阳性4例，HBV和HCV同时阳性1例。所有患者均以血小板减少为首发表现，没有肝硬化、门静脉高压或脾脏明显增大的证据。9例患者获得完全反应（CR），6例部分反应（PR），2例次要反应（MR），CR率45％，总有效率85％，血小板反应持久。应用IFN-α治疗没有严重的不良反应。结论：IFN-α是治疗肝炎病毒相关性血小板减少症切实有效的方法。
Objective：To evaluate the efficacy of α-interferon （IFN-α） for the treatment of patients with hepatitis-virus related thrombocytopenia. Method： Twenty patients with hepatitis virus related thrombocytopenia were treated with IFN-α. IFN-α was given at the dose of 3MU subcutaneously twice a week for at least 2 months. Resuit：Among the 20 patients, 14 were males and 6 females, with median age of 36.5 years （7-50）. HBV （hepatitis B virus） infection was revealed in 15 patients, HCV （hepatitis C virus） in 4, HBV and HCV co-infection in 1. All the patients presented with thrombocytopenia as the chief complaint and no evidence of cirrhosis, portal hypertension or significant splenomegaly. Complete response （CR） was achieved in 9 patients, partial response （PR） in 6 and minor response （MR） in 2. CR rate was 45% and overall response rate （OR） was 85%. Sustained platelet response was observed. There was no severe side-effect of IFN-α. Conclusion： IFN-α might be practicable and effective for the treatment of patients with hepatitis virus related thrombocytopenia.
出处
《临床血液学杂志》
CAS
2008年第3期229-232,共4页
Journal of Clinical Hematology
作者简介
杨仁池，E-mail：rcyang65@163．com
